ACT for NASH and NAFLD: Addressing Fatty Liver at the Cellular Level | ALIV

Non-alcoholic steatohepatitis (NASH) — the progressive inflammatory form of fatty liver disease, now more precisely termed metabolic dysfunction-associated steatohepatitis (MASH) — is one of the most common serious liver conditions in India's urban population. Unlike simple fatty liver (steatosis), NASH involves active hepatocellular inflammation and progressive fibrosis that can advance to cirrhosis in 20–30% of patients over fifteen to twenty years. Despite decades of research, no pharmacological therapy has achieved regulatory approval for NASH in India as of ALIV's current clinical period — making regenerative approaches like ACT genuinely relevant for a condition where conventional medicine has a clear gap.

Why NASH Creates a Specific ACT Opportunity

NASH is driven by a specific pathological sequence: hepatic fat accumulation → oxidative stress → hepatocellular inflammation (NLRP3 inflammasome activation, TNF-α, IL-1β) → hepatic stellate cell activation → fibrosis (collagen deposition replacing functional liver architecture). ACT targets multiple steps in this sequence. MSC-derived IL-10 and TGF-β regulatory signals suppress the NLRP3 inflammasome-driven inflammation; HGF-rich bone marrow preparations directly support hepatocyte survival and regeneration while modulating hepatic stellate cell activation (the key fibrosis driver); and VEGF supports the hepatic sinusoidal blood supply that delivers oxygen and nutrients to hepatocytes in the fibrotic liver where normal blood flow is disrupted. The mechanistic alignment between NASH pathology and ACT's growth factor profile is strong — stronger than for many of the pharmaceutical approaches that have failed in NASH trials, which targeted single mechanisms in a multifactorial disease.

Who Is an Appropriate NASH ACT Candidate

ALIV's ACT programme for NASH is most appropriate for patients with: fibrosis stage F2–F3 (histologically confirmed or estimated by FibroScan/elastography); NAS (NAFLD Activity Score) of 4 or above indicating active inflammatory disease; ongoing lifestyle modification commitment (without lifestyle modification — diet, weight management, exercise — ACT cannot produce sustained benefit against the ongoing metabolic driver); absence of cirrhosis complications (compensated disease); and ideally, a metabolic profile being actively managed (insulin resistance addressed, blood glucose managed). Patients with advanced cirrhosis (F4) require hepatology and transplant consultation rather than primary ACT consideration. See: ACT for liver conditions.

How does ACT complement lifestyle modification for NASH?

Lifestyle modification — particularly weight loss of 7–10% — is the most effective intervention for NASH, producing meaningful fibrosis regression in responsive patients. The challenge is that the inflammatory and fibrotic changes of established NASH persist for months to years even after the metabolic driver is addressed by weight loss — the liver's anti-fibrotic remodelling is slow. ACT in the context of ongoing lifestyle modification addresses the hepatic microenvironment — accelerating the anti-fibrotic and pro-regenerative shift that lifestyle modification has initiated, rather than replacing the lifestyle work. The combination produces more rapid fibrosis regression than lifestyle alone in the clinical experience at ALIV.

What blood tests show NASH response to ACT?

Primary markers: ALT and AST (hepatocellular inflammation markers — typically the first to respond); GGT (sensitive to hepatic oxidative stress); ferritin (elevated ferritin is both a NASH severity marker and an inflammatory marker — reduction reflects both). Secondary markers: FibroScan or liver elastography at six months (measures fibrosis reduction); fasting insulin and HOMA-IR (reflecting the insulin resistance driving NASH); and triglycerides (often elevated in NASH, reflecting the hepatic lipid metabolism dysfunction). A meaningful response at three months typically shows ALT/AST reduction of 20% or more; fibrosis assessment at six months provides the structural evidence of tissue-level response.